The effect of recombinant tissue plasminogen activator on MMP-2 and MMP-9 activities in vitro

Neurological Research

Volumn 37, Issue 1, 2015, Pages 9-13

  Golab, Piotr ^a   Kielbus, Michal ^b   Bielewicz, Joanna ^c   Kurzepa, Jacek ^b  

^a Department of Internal Medicine The Holy Family Specialist Hospital   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c University Hospital No 4   (Poland)

Author keywords

MMP 2; MMP 9; RtPA; Zymography

Indexed keywords

ALTEPLASE; GELATINASE A; GELATINASE B; FIBRINOLYTIC AGENT; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; IN VITRO STUDY; INCUBATION TIME; NORMAL HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PROCESSING; ZYMOGRAPHY; BLOOD; DOSE RESPONSE;

DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84919332825     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132814Y.0000000412     Document Type: Article

References (21)

1. Szczepańska-Szerej A, Kurzepa J, Wojczal J, Stelmasiak Z. Simvastatin-induced prevention of the increase in TNF-alpha level in the acute phase of ischemic stroke. Pharmacol Rep. 2007;59:94-7.
2. Gross H, Sung G, Weingart SD, Smith WS. Emergency neurological life support: acute ischemic stroke. Neurocrit Care. 2012;17(Suppl 1):S29-36.
3. Zhang JB, Ding ZY, Yang Y, Sun W, Hai F, Sui XN, et al. Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation. Neurol Res. 2010;32:353-8.
4. Adibhatla RM, Hatcher JF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets. 2008;7:243-53.
5. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke. 2002;33:831-6.
6. Tang J, Li YJ, Li Q, Mu J, Yang DY, Xie P. Endogenous tissue plasminogen activator increases hemorrhagic transformation induced by heparin after ischemia reperfusion in rat brains. Neurol Res. 2010;32:541-6.
7. Kurzepa J, Bielewicz J, Grabarska A, Stelmasiak Z, Stryjecka-Zimmer M, Bartosik-Psujek H. Matrix metalloproteinase-9 contributes to the increase of tau protein in serum during acute ischemic stroke. J Clin Neurosci. 2010;17:997-9.
8. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis. 2010;38:376-85.
9. Kelly MA, Shuaib A, Todd KG. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp Neurol. 2006;200:38-49.
10. Olson MW, Bernardo MM, Pietila M, Gervasi DC, Toth M, Kotra LP, et al. Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem. 2000;275:2661-8.
11. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002; 105:1679-85.
12. Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999;30:34-9.
13. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Quintana M, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke. 2004;35:2123-7.
14. Gilligan AK, Markus R, Read S, Srikanth V, Hirano T, Fitt G, et al. Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke. 2002;33:2236-42.
15. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo´ M, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598-603.
16. Kupai K, Szucs G, Cseh S, Hajdu I, Csonka C, Csont T, et al. Matrix metalloproteinase activity assays: Importance of zymography. J Pharmacol Toxicol Methods. 2010;61:205-9.
17. Ribbens C, Martin M, Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis. 2002;61:161-6.
18. Cederholm-Williams SA. Concentration of plasminogen and antiplasmin in plasma and serum. J Clin Pathol. 1981;34:979-81.
19. Winkler F, Kastenbauer S, Koedel U, Pfister HW. Increased serum concentrations of tissue plasminogen activator correlate with an adverse clinical outcome in patients with bacterial meningitis. J Neurol Neurosurg Psychiatry. 2002;73:456.
20. Ogata N, Ogawa H, Ogata Y, Numata Y, Morigami Y, Suefuji H, et al. Comparison of thrombolytic therapies with mutant tPA (lanoteplase/SUN9216) and recombinant tPA (alteplase) for acute myocardial infarction. Jpn Circ J. 1998;62:801-6.
21. Kurzepa J, Stryjecka-Zimmer M, Szczepanska-Szerej A, Kurzepa J. The influence of hydrophilic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (pravastatin) on gelatinase activity in vitro. Pharmaceut Biol. 2009;47:924-6.